Departments of Surgery and Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, 72-160 CHS, Los Angeles California 90095, USA.
Infectious Disease Units, Departments of Pediatrics and Medicine, Massachusetts General Hospital East, 149 13th Street, Fifth Floor, Charlestown, Massachusetts 02129, USA.
Nat Rev Drug Discov. 2014 Oct;13(10):741-58. doi: 10.1038/nrd4368. Epub 2014 Sep 5.
Sepsis, a common and potentially fatal systemic illness, is triggered by microbial infection and often leads to impaired function of the lungs, kidneys or other vital organs. Since the early 1980s, a large number of therapeutic agents for the treatment of sepsis have been evaluated in randomized controlled clinical trials. With few exceptions, the results from these trials have been disappointing, and no specific therapeutic agent is currently approved for the treatment of sepsis. To improve upon this dismal record, investigators will need to identify more suitable therapeutic targets, improve their approaches for selecting candidate compounds for clinical development and adopt better designs for clinical trials.
脓毒症是一种常见且可能致命的全身性疾病，由微生物感染引发，常导致肺部、肾脏或其他重要器官功能障碍。自 20 世纪 80 年代初以来，大量治疗脓毒症的药物已在随机对照临床试验中进行了评估。除了少数例外，这些试验的结果令人失望，目前尚无专门用于治疗脓毒症的治疗药物获得批准。为了改善这种惨淡的局面，研究人员需要确定更合适的治疗靶点，改进选择候选化合物进行临床开发的方法，并采用更好的临床试验设计。
